EDSA
Edesa Biotech·NASDAQ
--
--(--)
--
--(--)
5.23 / 10
Netural
Funding flows are rated 6.78/10, reflecting robust inflows despite negative block and medium-size trends. Analyst coverage is sparse—only one active analyst with a Strong Buy rating—yet the consensus is bullish. The mismatch between positive flow, limited bullish analyst view, and weak fundamentals keeps the overall outlook neutral.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-03
InstitutionHC Wainwright & Co.
Times predicted2
Historical Win Rate50.0%
What is the market sentiment for EDSA?
- EDSA holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.23/10 (Netural).
